Group 1: Marketing Reform and Growth - The company completed a marketing organizational restructuring by the end of 2020, increasing the marketing staff from 80 to approximately 140 people, with plans for further expansion in 2021 [1] - The immune and molecular product lines have maintained stable and rapid growth, achieving a strong market position [1] Group 2: Product Development and Market Strategy - The company aims to leverage the in vitro diagnostic industry and domestic substitution policies to gain a larger market share [3] - The flow cytometry technology used for autoimmune detection products offers advantages such as rapid joint testing, full automation, and digital results, expected to become a significant product in the next 3 to 5 years [3] - The company plans to increase the installation of flow cytometry and chemiluminescence instruments to ensure stable reagent revenue [3] Group 3: Revenue and Product Lines - The revenue from tumor markers is expected to grow steadily due to the results of marketing reforms and the stable output of previously deployed instruments [3] - The company’s molecular products include HPV nucleic acid detection, companion diagnostics, and cancer detection products, with HPV being a key focus [5] - The company plans to introduce cartridge-based PCR detection products, which will overcome laboratory space and personnel limitations, potentially becoming an important technology platform for future molecular detection [5]

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2021004 | --- | --- | --- | --- | --- | --- | |-------------------------|-------|-----------------------------------------------------------|-------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------| | 投资者关系 活动类别 | | 特定对象调研 □媒体采访 \n□新闻发布会 \n□现场参观 | \n \n□其他： | 业绩说明会 □路演活动 | □分析师会议 | | 参与单位名称 及人员姓名 | | 通过全景网"投资者关系互动平台"（ 度网上业绩 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2021006 | --- | --- | --- | --- | --- | |------------------------------------------|-------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------------------| | 投资者关系 活动类别 | | 特定对象调研 \n□新闻发布会 □业绩说明会 \n□现场参观 □其他： | □媒体采访 □分析师会议 \n \n | □路演活动 | | 参与单位名称 及人员姓名（排 名不分先后） | | | 国海证券许睿、朱凤萍，华安证券黎一江、方晨、王雨晴 | | | 时 间 | ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2022004 | --- | --- | --- | --- | --- | |------------------------------------------|-------|---------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | | □新闻发布会 \n□现场参观 | □特定对象调研 □媒体采访 □分析师会议 \n | □业绩说明会 □路演活动 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 2021 年度业绩说明会 投资者活动记录表 编号：IR-2022003 | --- | --- | --- | --- | |-------------------|--------------------------------------------------------------------------------|--------------------------------------------------|-------------------------------| | | | | | | | □特定对象调研 □分析师会议 | | | | | □媒体采访 | 业绩说明会 | | | 投资者关系活动类 | □新闻发布会 □路演活动 | | | | 别 | □现场参观 □电话会议 | | | | | □其他：（请文字说明其他活动内容） | | | | 参与单位名称 | 透景生命 2021 年度业绩说明会采用网络远程方式进行，面向全体投资者 | | | | 及人员姓名 | | | | | 时间 | 2022 年 5 月 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2022006 | --- | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------| | 投资者关系 活动类别 | □新闻发布会 \n 现场参观 | □特定对象调研 □媒体采访 □分析师会议 \n□业绩说明会 □路演活动 \n□其他： | | | | | | 国金证券赵骁翔、汝吉瑞、开源证券岑峻宇、湘财证券陈澈、德邦证券韩力 | | | | | 嵬、招商证券黄力源、中 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2022005 | --- | --- | --- | --- | --- | |------------------------------------------|-------|----------------------------------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | ...

Financial Performance - Revenue for Q3 2022 reached ¥197,841,491, representing a 31.10% increase compared to ¥150,907,300 in the same period last year[5] - Net profit attributable to shareholders was ¥44,886,091, a 45.96% increase from ¥30,752,980 in Q3 2021[5] - Basic earnings per share for Q3 2022 was ¥0.2754, up 45.64% from ¥0.1891 in the same quarter last year[5] - Total operating revenue for the third quarter reached ¥518,469,451.66, an increase of 14.2% compared to ¥454,195,152.36 in the same period last year[21] - The net profit for Q3 2022 was CNY 87,702,033.20, a decrease of 17.0% compared to CNY 105,562,565.63 in Q3 2021[22] - Operating profit for Q3 2022 was CNY 94,452,589.88, down from CNY 119,022,723.70 in the same period last year, reflecting a decline of 20.7%[22] Cash Flow - Operating cash flow for the year-to-date period increased by 60.74% to ¥130,540,100 compared to ¥81,213,460 in the previous year[5] - Cash flow from operating activities improved by 60.74%, reaching ¥130,540,188.44, due to reduced payments and tax deferrals[11] - Cash flow from operating activities increased to CNY 130,540,188.44, compared to CNY 81,213,462.85 in Q3 2021, representing a growth of 60.7%[24] - Cash flow from investing activities showed a significant decrease of 96.19%, with a net of -¥5,030,771.05, due to reduced financial investments and fixed asset investments[11] - The total cash inflow from investment activities was CNY 873,165,092.50, a decrease from CNY 1,343,527,020.57 in the previous year, reflecting a decline of 35.0%[24] - The net cash flow from financing activities was -CNY 50,104,223.89, worsening from -CNY 26,606,406.30 in Q3 2021[24] Assets and Liabilities - Total assets as of September 30, 2022, were ¥1,576,314,672.21, reflecting a 5.17% increase from ¥1,498,842,208.60 at the beginning of the year[10] - The company reported a 44.15% increase in cash and cash equivalents, totaling ¥268,426,629.11 compared to ¥186,212,002.57 at the start of the year[10] - The company's total liabilities increased by 39.90% in accounts payable, reaching ¥58,432,712.46 due to increased credit purchases[10] - Total liabilities increased to ¥137,577,474.26, compared to ¥102,586,486.72, reflecting a rise of 34.2%[19] - The company's equity attributable to shareholders was ¥1,429,517,677.79, up from ¥1,393,830,622.64, indicating a growth of 2.6%[20] Expenses - Operating revenue increased significantly, leading to a 54.49% rise in operating costs, totaling ¥229,974,055.22 compared to ¥148,863,401.80 in the previous period[11] - Total operating costs amounted to ¥444,813,936.71, up 25.1% from ¥355,308,531.85 year-on-year[21] - Tax and additional charges rose by 118.85% to ¥4,476,965.60, primarily due to increased sales revenue and new property taxes[11] - The company reported a 44.02% decrease in income tax expenses to ¥6,550,802.48, reflecting a decline in profits compared to the previous period[11] - Research and development expenses were ¥53,510,582.27, reflecting an increase of 7.5% from ¥49,629,971.09 in the previous year[21] Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[5] - The company plans to continue investing in new product development and market expansion strategies to drive future growth[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,306, with no preferred shareholders[12] - The largest shareholder, Yao Jian'er, holds 19.99% of shares, totaling 32,753,700, with 24,565,275 shares pledged[12] Other Financial Metrics - Non-operating income for the year-to-date period totaled ¥3,833,393.49, down from ¥18,231,422.80 in the previous year[7] - Investment income increased by 39.13% to ¥13,629,436.42, driven by higher profits from equity method accounted companies[11] - The company experienced a total comprehensive income of CNY 87,702,033.20 for Q3 2022, compared to CNY 105,562,565.63 in the same quarter of the previous year, a decrease of 17.0%[22] - The company reported a decrease in credit impairment losses to -CNY 9,468,248.45 from -CNY 4,558,281.89 in Q3 2021, indicating a worsening in credit quality[22]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching RMB 100 million, representing a growth of 25% compared to the same period last year[13]. - The company's total revenue for the reporting period was ¥320,628,002.05, representing a 5.72% increase compared to the same period last year[28]. - The company's revenue for the reporting period reached 320.63 million yuan, representing a year-on-year increase of 5.72%[41]. - The revenue from reagents decreased by 17.19% year-on-year, amounting to 209.97 million yuan[41]. - The revenue from instruments saw a significant increase of 131.40%, partially offsetting the decline in reagent sales[41]. - The company's net profit attributable to shareholders was ¥43,111,720.79, a decrease of 42.37% year-over-year[28]. - Net profit for the first half of 2022 was CNY 43.05 million, a decrease of 42.5% from CNY 74.81 million in the first half of 2021[169]. - The company reported a net loss of 69.50 million yuan for the current period, compared to a profit in the previous period[180]. User Engagement and Market Expansion - User data showed an increase in active users, with the number of users growing by 15% year-over-year, reaching 1.5 million active users by the end of June 2022[13]. - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 30% year-over-year, driven by new product launches and market expansion efforts[13]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share in the region by the end of 2023[13]. - The company aims to expand its overseas market presence and has been actively exploring international distribution channels[28]. - The company plans to expand its market presence and product offerings in response to industry trends and challenges[87]. Research and Development - Research and development expenses increased by 20% in the first half of 2022, totaling RMB 10 million, as the company focuses on developing new technologies and products[13]. - The company’s R&D center is responsible for the design, research, and development of in vitro diagnostic products, with departments focusing on immunology, molecular biology, biochemistry, and mass spectrometry[47]. - The company is focused on continuous innovation and new product development, although there are risks associated with the success of R&D and regulatory approvals[83]. - The company has developed over 20 tumor marker detection products, making it one of the most comprehensive companies in this field in China[29]. Product Development and Technology - The company has developed tumor marker detection kits using flow cytometry and chemiluminescence technology, enabling rapid multi-marker detection and high sensitivity[34]. - The high-risk HPV nucleic acid detection kit can test 27 subtypes, including 17 high-risk and 10 low-risk types, providing comprehensive solutions for cervical cancer screening[35]. - The company has established a cleanroom production facility compliant with medical device production regulations, ensuring product quality and safety[38]. - The company has launched a highly integrated automated sample processing machine, which is expected to enhance testing speed and throughput for various molecular products[41]. - The company has established a high-throughput flow cytometry technology platform and a high-throughput immunofluorescence technology platform, enhancing its product offerings in multi-indicator detection[53]. Financial Position and Cash Flow - The total assets at the end of the reporting period were ¥1,532,499,427.37, reflecting a 2.25% increase from the end of the previous year[28]. - The net cash flow from operating activities increased by 66.46% to ¥113,611,557.58 compared to the previous year[28]. - The company's cash and cash equivalents increased by 367.10% to ¥66,610,018.74, due to improved collections and reduced outflows from investment activities[61]. - The total liabilities increased to CNY 146,677,102.15 from CNY 102,586,486.72, representing a significant rise of about 43%[164]. - Cash inflows from operating activities amounted to CNY 374,267,079.28, an increase of 20.9% from CNY 309,365,053.51 in the first half of 2021[173]. Risk Management - The company has identified potential risks related to regulatory changes and market competition, and has outlined measures to mitigate these risks in its management discussion[13]. - The company faces risks from the ongoing COVID-19 pandemic, which may impact the detection volume from its main customers, including medical institutions and testing centers[81]. - The company is exposed to risks from changes in industry policies, which could affect its customer structure and product pricing strategies[81]. - The company has established a strict quality management system to mitigate product quality risks, adhering to various international standards[82]. Environmental and Social Responsibility - The company adheres to environmental protection policies, implementing measures to treat wastewater, waste gas, noise, and solid waste[101]. - The company achieved a significant focus on environmental protection and energy conservation, completing ISO14001 and ISO45001 certifications[109]. - The company actively participated in public welfare activities, receiving multiple awards for its contributions to social responsibility[111]. - The company established a comprehensive employee welfare system, including social security, medical insurance, and housing funds[111]. Corporate Governance and Shareholder Commitments - The commitments made by the actual controllers, shareholders, and related parties have been fulfilled during the reporting period[114]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[117]. - The company has made commitments to avoid conflicts of interest and ensure compliance with corporate governance[116]. - The company did not experience any major litigation or arbitration matters during the reporting period[121].

Financial Performance - The company's revenue for Q1 2022 was CNY 145,099,766.40, representing a 22.30% increase compared to CNY 118,644,884.85 in the same period last year[3]. - Net profit attributable to shareholders decreased by 77.10% to CNY 5,270,134.33 from CNY 23,009,426.95 year-on-year[3]. - The net profit after deducting non-recurring gains and losses fell by 85.51% to CNY 3,065,114.09 compared to CNY 21,148,067.54 in the previous year[3]. - The company's basic and diluted earnings per share both decreased by 77.30% to CNY 0.032 from CNY 0.141 year-on-year[3]. - The net profit for the reporting period experienced a substantial decline compared to the previous year[12]. - Net profit for Q1 2022 was CNY 5,242,502.79, a decrease of 77.2% from CNY 23,009,426.95 in Q1 2021[18]. - The total comprehensive income for Q1 2022 was CNY 5,242,502.79, down from CNY 23,009,426.95 in Q1 2021[18]. Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 69,670,388.41, a 314.50% increase from a negative CNY 32,479,670.99 in the same period last year[3]. - The net cash flow from investment activities was CNY 58,012,186.31, a 226.75% increase compared to a negative CNY 45,769,375.97 in the previous year[9]. - The company experienced a 164.46% decrease in net cash flow from financing activities, amounting to CNY -6,513,798.27, due to share buybacks in the secondary market[9]. - Cash inflow from operating activities was CNY 194,746,627.61, compared to CNY 147,433,811.68 in Q1 2021, representing a growth of 32.0%[20]. - The net cash flow from operating activities was ¥69,670,388.41, a significant improvement compared to the previous period's net cash flow of -¥32,479,670.99[21]. - The net cash flow from investing activities was ¥58,012,186.31, recovering from a negative cash flow of -¥45,769,375.97 in the previous period[21]. - The company reported a cash outflow of ¥6,513,798.27 related to financing activities, compared to ¥158,487.66 in the previous period[21]. Assets and Liabilities - Total assets increased by 1.63% to CNY 1,523,258,716.68 from CNY 1,498,842,208.60 at the end of the previous year[3]. - The total liabilities at the end of Q1 2022 were CNY 126,601,913.16, an increase from CNY 102,586,486.72 at the beginning of the year[16]. - The company's current liabilities totaled CNY 106.15 million, up from CNY 81.44 million at the beginning of the year[15]. - Total equity attributable to shareholders of the parent company was CNY 1,394,259,335.82, slightly up from CNY 1,393,830,622.64 at the beginning of the year[16]. - The total assets of the company as of March 31, 2022, amounted to CNY 1,523.26 million, an increase from CNY 1,498.84 million at the beginning of the year[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 22,134[10]. - The largest shareholder, Yao Jian'er, holds 19.98% of the shares, amounting to 32,753,700 shares, with 2,826,000 shares pledged[10]. - The second-largest shareholder, Lingfei Group Co., Ltd., holds 9.28% of the shares, totaling 15,213,059 shares, with 5,580,000 shares pledged[10]. Operational Insights - The company's operating costs rose by 93.31% to CNY 71,603,875.56, primarily due to increased sales revenue and a higher proportion of agency products[8]. - The main products, tumor-related testing products, saw a significant decrease in procurement from clients in Beijing and Guangdong due to the pandemic[12]. - Despite the increase in marketing for COVID-19 testing instruments and consumables, the gross margin for these products is significantly lower than that of the company's proprietary testing reagents[12]. - The company expects sales of its main products to recover to normal levels following an improvement in the pandemic situation[12]. - Research and development expenses for Q1 2022 were CNY 16,680,429.10, an increase from CNY 15,540,837.73 in Q1 2021[17]. - The company reported a decrease in investment income to CNY 2,421,856.89 from CNY 4,253,121.99 in the previous year[17]. Other Financial Metrics - Total operating revenue for Q1 2022 was CNY 145,099,766.40, an increase of 22.3% compared to CNY 118,644,884.85 in the same period last year[17]. - Total operating costs for Q1 2022 were CNY 143,034,447.06, up 48.7% from CNY 96,225,957.17 in Q1 2021[17]. - The company did not receive any cash from investment in the current period, while it received ¥341,000,000.00 in the previous period[21]. - The report for the first quarter was not audited[22].